Q4 2024 Earnings Call Transcript April 10, 2025 CureVac N.V. misses on earnings expectations. Reported EPS is $-0.16564 EPS, ...

Breast Cancer Animal Studies Show Unprecedented Anti-Cancer Efficacy of 100% Tumor Growth Inhibition HONG KONG, CHINA / ACCESS Newswire / April 11, 2025 / CK Life Sciences Int'l., (Holdings) Inc. ("CK ...

In the default model, the graph representing each individual enhancer can be arbitrarily complicated. To show how the ABC Score formula can arise from the default model, we need to impose the further ...

A team of University of Kentucky Markey Cancer Center researchers has found the mechanism that grants prostate cancer ...

CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2024 and Provides Business Update 10.04.2025 / 13:12 CET/CEST The issuer is solely responsible for the content of this ...

Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicine company ...

Writing in Molecular Therapy Nucleic Acids, researchers hypothesized that using poly(A) tail mimetics to enhance mRNA expression from haploinsufficiency-associated genes could be a disease-modifying ...

Combining mRNA with a specialised lipid nanoparticle could reach areas of the lungs previously inaccessible to conventional ...

Ethris has partnered Lonza for the development of room-temperature stable mRNA vaccine candidates targeting respiratory ...

The FDA has granted clearance to CureVac's IND for the open-label Phase I trial of CVHNLC in individuals with sqNSCLC.

Esophageal basaloid squamous cell carcinoma (EBSCC) is a rare type of esophageal squamous cell cancer (ESCC) characterized by basaloid features and considered to be more aggressive than ESCC. RNA ...

Discover how an emerging technology called tRNA therapy could become the next big thing in genetic disease treatment.